NAD+ is one of the most talked-about molecules in longevity research. Every cell in your body uses it for energy production, DNA repair, and the activation of sirtuins, proteins associated with healthy aging. The problem is that NAD+ levels fall by roughly 50% between age 40 and 60, and that decline is linked to many hallmarks of aging.
Two categories of supplements claim to address this: NMN (nicotinamide mononucleotide) and “NAD+” products themselves. They are not the same thing. Understanding the difference matters if you are going to spend money on either.
Quick Comparison
| Property | NMN | Direct NAD+ |
|---|---|---|
| What it is | NAD+ precursor, one metabolic step from NAD+ | The coenzyme itself |
| Oral bioavailability | Well absorbed, raises blood NAD+ in trials | Poor: large molecule with limited cellular uptake |
| Human RCT evidence | Multiple trials through 2024 | Minimal direct supplementation trials |
| Typical dose | 250–600 mg/day | Variable, often 250–500 mg |
| Evidence grade | B (growing) | C (limited direct trial data) |
| Cost | Higher | Similar or higher |
| Best for | Raising intracellular NAD+ with documented human evidence | Not clearly supported by human data |
What Is NAD+ and Why Does It Decline?
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell. It is essential for:
- Oxidative phosphorylation: converting food into ATP, the cell’s energy currency
- Sirtuin activation: NAD+-dependent proteins that regulate gene expression, stress responses, and longevity pathways
- PARP enzymes: DNA damage repair proteins that consume NAD+ as fuel
- CD38 activity: an enzyme whose activity increases with age, burning through NAD+
The decline in NAD+ with age is well documented. A 2018 review (PMID 29514064) titled “Therapeutic Potential of NAD-Boosting Molecules” in Cell Metabolism catalogued the in vivo evidence and concluded that restoring NAD+ levels shows broad therapeutic promise across metabolic, cardiovascular, and neurodegenerative contexts.
The challenge is how to restore it.
Why You Cannot Simply Take NAD+ Orally
NAD+ is a large, charged molecule. Cell membranes are designed to exclude large polar molecules unless specific transporters are present. Oral NAD+ does get absorbed from the gut to some degree, but most of it is broken down before it reaches tissues where it is needed. The fraction that enters cells is limited.
This is why the field has focused on NAD+ precursors, smaller molecules that cells convert to NAD+ after uptake. The main precursors studied in humans are:
- NMN (nicotinamide mononucleotide): one enzymatic step from NAD+
- NR (nicotinamide riboside): two steps from NAD+
- Niacin (NA) and niacinamide (NAM): older, less targeted precursors
NMN sits closest to NAD+ in the biosynthesis pathway, which has made it a primary research target in recent years.
For a direct comparison of NMN and NR, see the NMN vs NR guide.
What the Human Trials Show for NMN
Yoshino et al., 2021 (Science)
One of the most cited human NMN trials to date is the Yoshino et al. study published in Science (PMID 33888596). This was a 10-week, randomized, placebo-controlled, double-blind trial in postmenopausal women with prediabetes. NMN supplementation at 250 mg daily significantly increased skeletal muscle NAD+ levels and improved muscle insulin sensitivity, as measured by hyperinsulinemic-euglycemic clamp, the gold standard for insulin sensitivity measurement.
This was significant because it moved NMN beyond blood NAD+ elevation and showed tissue-level effects with functional metabolic implications.
Igarashi et al., 2022: Dose-Dependent RCT
A randomized, multicenter, double-blind, placebo-controlled, parallel-group trial (PMID 36482258) enrolled 80 healthy middle-aged adults for 60 days. Participants received placebo, 300 mg/day NMN, or 600 mg/day NMN. Both NMN doses significantly raised blood NAD+ levels compared to placebo, in a dose-dependent manner. The trial confirmed clinical safety with no serious adverse events across all groups.
Igarashi et al., 2023: Older Adults with Diabetes
A follow-up prospective study (PMID 36443648) tested NMN in older patients with diabetes and impaired physical performance over 24 weeks. The primary endpoints were grip strength and walking speed. While NMN did not improve grip strength significantly, there were favorable trends in other metabolic and physical markers, and safety was confirmed over the longer duration.
Yamane et al., 2023: NAD+ and Arterial Stiffness
A study on long-term NMN supplementation (PMID 36797393) examined NAD+ metabolism and arterial stiffness in older adults. It documented NAD+ level changes with NMN use and assessed cardiovascular markers over time. The study added to the safety profile and mechanistic data on NMN’s systemic effects.
Irie et al., 2023: Walking Speed and Sleep
A study (PMID 38789831) found that ingestion of beta-NMN increased blood NAD+ levels in participants and was associated with maintenance of walking speed and improvement in sleep quality. This trial is notable because it captured functional outcomes beyond biomarkers.
2024 Meta-Analysis: Glucose and Lipid Metabolism
A 2024 systematic review and meta-analysis (PMID 39531138) pooled randomized controlled trial data on NMN’s effects on glucose and lipid metabolism in adults. The analysis confirmed that NMN supplementation raises NAD+ levels and found favorable trends in metabolic markers, though the authors noted that longer-duration trials are still needed to establish the magnitude of effects.
Safety
A 24-week placebo-controlled safety study (PMID 36002548) in healthy adult men and women found no serious adverse events at doses up to 900 mg/day. Blood chemistry panels, vital signs, and safety biomarkers remained within normal limits throughout. Mild GI side effects were the most commonly reported issues, and they were not significantly different from placebo.
This safety profile is a meaningful data point given the long-term nature of any anti-aging supplementation strategy.
NMN vs NAD+ Products: The Practical Answer
If you are choosing between NMN and products labeled as “NAD+” supplements:
Choose NMN. The human clinical trial evidence for NMN is substantially stronger than for oral NAD+ itself. Multiple RCTs confirm NMN raises blood NAD+ levels in a dose-dependent manner, with clean safety data over 60 to 168 days.
Products selling “NAD+” directly either contain NAD+ in a form with limited bioavailability, or they use sublingual/IV delivery methods that bypass the absorption problem. These come at much higher cost and less convenient administration.
How NMN Compares to NR
NR (nicotinamide riboside) is the other well-studied NAD+ precursor. It has more published human trial data overall and is generally less expensive. The trade-off is that NR requires one additional enzymatic conversion to reach NAD+, compared to NMN’s single step.
Both raise blood NAD+ levels in humans. The choice often comes down to cost, availability, and individual response. See the dedicated NMN vs NR comparison guide for a side-by-side breakdown.
Dosage
Based on the available RCT data:
- 250 mg/day: the dose used in the Yoshino Science trial, with significant muscle NAD+ and insulin sensitivity effects
- 300–600 mg/day: the range from the Igarashi multicenter RCT, both doses raised blood NAD+ significantly
- 900 mg/day: highest dose tested in safety studies, well tolerated
For most healthy adults starting NMN, 250 to 500 mg per day is a reasonable range supported by clinical data. Higher doses have been safely tested but provide diminishing returns on NAD+ elevation relative to cost.
For detailed guidance on when to take NMN and the morning vs night timing question, see the NMN ingredient page.
What NMN Cannot Do
NMN research is exciting, but it is important to read that excitement accurately.
Most human trials are short (8 to 24 weeks). The longevity effects seen in animal models (extended lifespan, reversal of specific aging pathologies) have not been replicated in humans because those studies have not been conducted. What the human data shows is that NMN safely raises NAD+ levels and improves specific biomarkers. Whether that translates to longer, healthier lives in humans remains an open research question.
NMN is not a replacement for exercise, sleep, and diet. Those lifestyle factors have far more evidence for longevity impact than any supplement in this category.
FAQ
Should I take NMN or NAD+ directly? Most researchers recommend NMN over direct NAD+ supplementation. NAD+ is a large molecule that does not easily cross cell membranes, making oral NAD+ supplementation less effective at raising intracellular levels. NMN is a smaller precursor molecule that the body converts to NAD+ after absorption. Multiple human clinical trials confirm that oral NMN raises blood NAD+ levels in a dose-dependent manner.
What does NMN do for anti-aging? NMN raises NAD+ levels, which decline significantly with age. NAD+ is required for sirtuin activity (proteins linked to longevity), DNA repair via PARP enzymes, and mitochondrial energy production. Human trials have shown NMN supplementation may support muscle insulin sensitivity, walking speed in older adults, sleep quality, and metabolic markers. Evidence is promising but most human trials are still short-term.
How much NMN should I take daily? Clinical trials have used doses ranging from 250 mg to 900 mg per day. A randomized, dose-dependent trial (PMID 36482258) found that 300 mg and 600 mg daily for 60 days both raised blood NAD+ levels significantly with good safety profiles. Most researchers suggest 250 to 500 mg as a practical starting range for healthy middle-aged adults.
Is NMN safe for long-term use? Available evidence suggests NMN is well tolerated. A 24-week placebo-controlled safety study (PMID 36002548) in healthy adults found no serious adverse events at doses up to 900 mg per day. Blood chemistry, vital signs, and safety biomarkers remained stable throughout. Long-term data beyond 24 weeks in humans is still limited.
References
-
Rajman L, Chwalek K, Sinclair DA. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab. 2018;27(3):529–547. PMID 29514064
-
Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–1229. PMID 33888596
-
Igarashi M, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2022. PMID 36482258
-
Igarashi M, et al. Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance: A prospective, placebo-controlled, double-blind clinical trial. Geriatr Gerontol Int. 2023. PMID 36443648
-
Irie J, et al. Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults. NPJ Aging. 2023. PMID 38789831
-
Yamane T, et al. Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. Sci Rep. 2023. PMID 36797393
-
Yi W, et al. Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Nutr Metab Cardiovasc Dis. 2024. PMID 39531138
-
Fukamizu Y, et al. Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women. Sci Rep. 2022. PMID 36002548